GlaxoSmithKline Pharmaceuticals has issued a certificate confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended December 31, 2025. The certificate, received from Kfin Technologies Limited, confirms the reconciliation of securities and their listing on stock exchanges. This ensures adherence to regulatory requirements regarding dematerialization.
Compliance Confirmation
GlaxoSmithKline Pharmaceuticals Limited confirms adherence to regulatory standards for the quarter ending December 31, 2025. This confirmation is in line with the requirements outlined in Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, dated January 8, 2026, has been issued to both the BSE Limited and the National Stock Exchange of India Limited.
Details of Certificate
The certificate, obtained from Kfin Technologies Limited, the Registrar and Share Transfer Agent, validates that all securities received for dematerialization during Q3 (Oct-Dec) 2025 were duly processed and confirmed. This ensures that the dematerialized securities are accurately reflected and listed on the relevant stock exchanges. All certificates have been verified and mutilated as per regulatory guidelines. The report was sent on January 8, 2026.
Source: BSE
